Maintenance of Alveolitis in Patients with Chronic Beryllium Disease by Beryllium-Specific Helper T Cells

Cesare Saltini, Karen Winestock, Martha Kirby, Paula Pinkston, Ronald Crystal

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

Chronic beryllium disease is characterized by the accumulation of helper/inducer T cells, macrophages, and granulomas in the lungs. To evaluate the hypothesis that the proliferation of CD4+ (helper/inducer) T cells in the lungs of patients with this disorder is maintained by local activation of beryllium-specific T-cell clones, we studied T cells obtained from peripheral blood and by bronchoalveolar lavage in eight patients and five healthy controls. The proliferation of T cells in response to beryllium in vitro was confined to the CD4+ T cells from the patients and was dependent on the presentation of antigen in the presence of both major histocompatibility complex class II antigens and functional interleukin-2 receptors. T cells from the patients' lungs had a significantly greater response to beryllium than did T cells from their peripheral blood (stimulation index, 103 vs. 5; P<0.01). Lines and clones of cells developed from T cells from the patients' lungs showed dose-dependent proliferation in response to beryllium but did not respond to recall antigens or to other metals. Although all beryllium-specific T-cell clones were CD4+ and none were CD8+ (suppressor/cytotoxic), all beryllium-specific clones studied had different rearrangements of T-cell antigen receptors, suggesting that the response to beryllium involved T cells with diverse specificities for beryllium. We conclude that in patients with chronic beryllium disease, beryllium acts as a class II–restricted antigen, stimulating local proliferation and accumulation in the lung of beryllium-specific CD4+ (helper/inducer) T cells. Hence, chronic beryllium disease is a hypersensitivity disease in which beryllium is the specific antigen. THE inhalation of beryllium dusts, salts, or fumes is associated with two types of pulmonary disease: an acute chemical pneumonitis caused by short exposures to high concentrations, and a chronic interstitial granulomatous lung disorder caused by lower levels of exposure over months to years.1 2 3 4 The acute pneumonitis is probably caused by direct injury of the lung by beryllium, whereas the chronic pulmonary disease is associated with an alveolitis characterized by a diffuse accumulation of lymphocytes and mononuclear phagocytes in the alveolar structures and the formation of noncaseating granulomas — features suggestive of a chronic, delayed-type hypersensitivity reaction.5 6 7 8 9 The concept that…

Original languageEnglish
Pages (from-to)1103-1109
Number of pages7
JournalNew England Journal of Medicine
Volume320
Issue number17
DOIs
Publication statusPublished - 27 Apr 1989
Externally publishedYes

Fingerprint

Berylliosis
Beryllium
Helper-Inducer T-Lymphocytes
Chronic Disease
Maintenance
T-Lymphocytes
Lung
Clone Cells
Granuloma
Antigens
Lung Diseases
Pneumonia
Interleukin-2 Receptors
Histocompatibility Antigens Class II
Antigen Presentation
Delayed Hypersensitivity
Lung Injury
Bronchoalveolar Lavage
Phagocytes
T-Cell Antigen Receptor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maintenance of Alveolitis in Patients with Chronic Beryllium Disease by Beryllium-Specific Helper T Cells. / Saltini, Cesare; Winestock, Karen; Kirby, Martha; Pinkston, Paula; Crystal, Ronald.

In: New England Journal of Medicine, Vol. 320, No. 17, 27.04.1989, p. 1103-1109.

Research output: Contribution to journalArticle

Saltini, Cesare ; Winestock, Karen ; Kirby, Martha ; Pinkston, Paula ; Crystal, Ronald. / Maintenance of Alveolitis in Patients with Chronic Beryllium Disease by Beryllium-Specific Helper T Cells. In: New England Journal of Medicine. 1989 ; Vol. 320, No. 17. pp. 1103-1109.
@article{3315b758429142c9962cb62f7e274ee7,
title = "Maintenance of Alveolitis in Patients with Chronic Beryllium Disease by Beryllium-Specific Helper T Cells",
abstract = "Chronic beryllium disease is characterized by the accumulation of helper/inducer T cells, macrophages, and granulomas in the lungs. To evaluate the hypothesis that the proliferation of CD4+ (helper/inducer) T cells in the lungs of patients with this disorder is maintained by local activation of beryllium-specific T-cell clones, we studied T cells obtained from peripheral blood and by bronchoalveolar lavage in eight patients and five healthy controls. The proliferation of T cells in response to beryllium in vitro was confined to the CD4+ T cells from the patients and was dependent on the presentation of antigen in the presence of both major histocompatibility complex class II antigens and functional interleukin-2 receptors. T cells from the patients' lungs had a significantly greater response to beryllium than did T cells from their peripheral blood (stimulation index, 103 vs. 5; P<0.01). Lines and clones of cells developed from T cells from the patients' lungs showed dose-dependent proliferation in response to beryllium but did not respond to recall antigens or to other metals. Although all beryllium-specific T-cell clones were CD4+ and none were CD8+ (suppressor/cytotoxic), all beryllium-specific clones studied had different rearrangements of T-cell antigen receptors, suggesting that the response to beryllium involved T cells with diverse specificities for beryllium. We conclude that in patients with chronic beryllium disease, beryllium acts as a class II–restricted antigen, stimulating local proliferation and accumulation in the lung of beryllium-specific CD4+ (helper/inducer) T cells. Hence, chronic beryllium disease is a hypersensitivity disease in which beryllium is the specific antigen. THE inhalation of beryllium dusts, salts, or fumes is associated with two types of pulmonary disease: an acute chemical pneumonitis caused by short exposures to high concentrations, and a chronic interstitial granulomatous lung disorder caused by lower levels of exposure over months to years.1 2 3 4 The acute pneumonitis is probably caused by direct injury of the lung by beryllium, whereas the chronic pulmonary disease is associated with an alveolitis characterized by a diffuse accumulation of lymphocytes and mononuclear phagocytes in the alveolar structures and the formation of noncaseating granulomas — features suggestive of a chronic, delayed-type hypersensitivity reaction.5 6 7 8 9 The concept that…",
author = "Cesare Saltini and Karen Winestock and Martha Kirby and Paula Pinkston and Ronald Crystal",
year = "1989",
month = "4",
day = "27",
doi = "10.1056/NEJM198904273201702",
language = "English",
volume = "320",
pages = "1103--1109",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - Maintenance of Alveolitis in Patients with Chronic Beryllium Disease by Beryllium-Specific Helper T Cells

AU - Saltini, Cesare

AU - Winestock, Karen

AU - Kirby, Martha

AU - Pinkston, Paula

AU - Crystal, Ronald

PY - 1989/4/27

Y1 - 1989/4/27

N2 - Chronic beryllium disease is characterized by the accumulation of helper/inducer T cells, macrophages, and granulomas in the lungs. To evaluate the hypothesis that the proliferation of CD4+ (helper/inducer) T cells in the lungs of patients with this disorder is maintained by local activation of beryllium-specific T-cell clones, we studied T cells obtained from peripheral blood and by bronchoalveolar lavage in eight patients and five healthy controls. The proliferation of T cells in response to beryllium in vitro was confined to the CD4+ T cells from the patients and was dependent on the presentation of antigen in the presence of both major histocompatibility complex class II antigens and functional interleukin-2 receptors. T cells from the patients' lungs had a significantly greater response to beryllium than did T cells from their peripheral blood (stimulation index, 103 vs. 5; P<0.01). Lines and clones of cells developed from T cells from the patients' lungs showed dose-dependent proliferation in response to beryllium but did not respond to recall antigens or to other metals. Although all beryllium-specific T-cell clones were CD4+ and none were CD8+ (suppressor/cytotoxic), all beryllium-specific clones studied had different rearrangements of T-cell antigen receptors, suggesting that the response to beryllium involved T cells with diverse specificities for beryllium. We conclude that in patients with chronic beryllium disease, beryllium acts as a class II–restricted antigen, stimulating local proliferation and accumulation in the lung of beryllium-specific CD4+ (helper/inducer) T cells. Hence, chronic beryllium disease is a hypersensitivity disease in which beryllium is the specific antigen. THE inhalation of beryllium dusts, salts, or fumes is associated with two types of pulmonary disease: an acute chemical pneumonitis caused by short exposures to high concentrations, and a chronic interstitial granulomatous lung disorder caused by lower levels of exposure over months to years.1 2 3 4 The acute pneumonitis is probably caused by direct injury of the lung by beryllium, whereas the chronic pulmonary disease is associated with an alveolitis characterized by a diffuse accumulation of lymphocytes and mononuclear phagocytes in the alveolar structures and the formation of noncaseating granulomas — features suggestive of a chronic, delayed-type hypersensitivity reaction.5 6 7 8 9 The concept that…

AB - Chronic beryllium disease is characterized by the accumulation of helper/inducer T cells, macrophages, and granulomas in the lungs. To evaluate the hypothesis that the proliferation of CD4+ (helper/inducer) T cells in the lungs of patients with this disorder is maintained by local activation of beryllium-specific T-cell clones, we studied T cells obtained from peripheral blood and by bronchoalveolar lavage in eight patients and five healthy controls. The proliferation of T cells in response to beryllium in vitro was confined to the CD4+ T cells from the patients and was dependent on the presentation of antigen in the presence of both major histocompatibility complex class II antigens and functional interleukin-2 receptors. T cells from the patients' lungs had a significantly greater response to beryllium than did T cells from their peripheral blood (stimulation index, 103 vs. 5; P<0.01). Lines and clones of cells developed from T cells from the patients' lungs showed dose-dependent proliferation in response to beryllium but did not respond to recall antigens or to other metals. Although all beryllium-specific T-cell clones were CD4+ and none were CD8+ (suppressor/cytotoxic), all beryllium-specific clones studied had different rearrangements of T-cell antigen receptors, suggesting that the response to beryllium involved T cells with diverse specificities for beryllium. We conclude that in patients with chronic beryllium disease, beryllium acts as a class II–restricted antigen, stimulating local proliferation and accumulation in the lung of beryllium-specific CD4+ (helper/inducer) T cells. Hence, chronic beryllium disease is a hypersensitivity disease in which beryllium is the specific antigen. THE inhalation of beryllium dusts, salts, or fumes is associated with two types of pulmonary disease: an acute chemical pneumonitis caused by short exposures to high concentrations, and a chronic interstitial granulomatous lung disorder caused by lower levels of exposure over months to years.1 2 3 4 The acute pneumonitis is probably caused by direct injury of the lung by beryllium, whereas the chronic pulmonary disease is associated with an alveolitis characterized by a diffuse accumulation of lymphocytes and mononuclear phagocytes in the alveolar structures and the formation of noncaseating granulomas — features suggestive of a chronic, delayed-type hypersensitivity reaction.5 6 7 8 9 The concept that…

UR - http://www.scopus.com/inward/record.url?scp=0024501760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024501760&partnerID=8YFLogxK

U2 - 10.1056/NEJM198904273201702

DO - 10.1056/NEJM198904273201702

M3 - Article

C2 - 2469014

AN - SCOPUS:0024501760

VL - 320

SP - 1103

EP - 1109

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -